RARE PHOTOS: 2 | Rare Historical Photos

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

MarketBeat · Feb 21

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

Barchart · Feb 10

Super Bowl ads try to overcome tough times with health, caring and the usual laughs

At a difficult time for America, Super Bowl advertisers are asking viewers to take care of themselves and others — and maybe even crack a smile

The Independent UK · Feb 8

Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results

Hims & Hers Health delivered a mixed earnings report and announced a potential Wegovy partnership with Novo Nordisk; the downside risk to HIMS stock looks low.

MarketBeat · Nov 5, 2025

Hims & Hers Short Interest Nears All-Time High, Buy The Dip?

Hims & Hers stock is falling well off its 52-week highs, as bears lean on the CEO's scheduled sale that just took place, though it might be a mistake.

MarketBeat · Oct 24, 2025

CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You?

Insider selling tests investor confidence as Hims & Hers faces valuation pressure and shifting GLP-1 momentum.

Barchart · Oct 21, 2025

Trump's Weight-Loss Drug Push May Put These ETFs On A Diet

The weight-loss industry that fueled one of Wall Street’s most popular ETF themes may finally be going on a crash diet.

Benzinga · Oct 17, 2025

Why Hims & Hers Health Shares Are Sliding Friday

Shares of Hims Hers Health Inc (NYSE:HIMS) are trading lower Friday morning after comments from President Donald Trump indicated that he expects the prices of popular weight-loss drugs to decrease. Here’s what investors need to know.

Benzinga · Oct 17, 2025

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price.

Benzinga · Oct 16, 2025

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem

Hims Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this time is not another flashy partnership — it's a rally built from within.

Benzinga · Oct 16, 2025